ABSTRACT Mucosal immunity provides a potential for preventing initial infection and stopping subsequent transmission of SARS-CoV-2. Here, we examined the safety and immunogenicity of a replication-defective adenovirus type-5 vectored vaccine (Ad5-nCov) encoding SARS-CoV-2 spike protein delivered by nebulization inhalation in rhesus macaques. The vaccine-associated clinical pathology and toxicity were not observed in the NHP model. The extensive safety study indicated that Ad5-nCoV was mainly confined to the organs related to respiratory system and was rapidly cleared away from the system. Our results showed that Ad5-nCoV delivered by inhalation robustly elicited both systematic and mucosal immune responses against SARS-nCoV-2 and variants. Thus, Ad5-nCoV inhalation may provide an effective, safe and non-invasive vaccination strategy for the control of SARS-CoV-2.
【저자키워드】 COVID-19, Safety, aerosol, SARS-CoV-2 vaccine, mucosal immunity, inhalation, immunoglobulin A, 【초록키워드】 SARS-CoV-2, pathology, immunogenicity, Immunity, Infection, Toxicity, variants, Spike protein, Clinical pathology, Adenovirus, Replication, immune responses, SARS-CoV-2 spike protein, inhalation, Respiratory system, respiratory, Ad5-nCoV, rhesus macaques, Vaccination strategy, Safe, Non-invasive, vectored vaccine, nCoV, organs, organ, transmission of SARS-CoV-2, NHP, mucosal immune, effective, initial, examined, indicated, subsequent, provide, elicited, responses against, 【제목키워드】 SARS-CoV-2, Adenovirus-vectored vaccine, rhesus macaque, mucosal,